Canadian Nuclear Laboratories Partners with Biotech Firms to Advance Cancer Treatment
CHALK RIVER -- Canadian Nuclear Laboratories (CNL) is collaborating with two leading Canadian healthcare biotech companies -- Repare Therapeutics and Defence Therapeutics -- on individual research projects through its Canadian Nuclear Research Initiative -- Health (CNRI-H) program.
Launched in 2021, the CNRI-H program is designed to accelerate the development of targeted radiopharmaceuticals in Canada through joint research projects related to oncology, targeted alpha therapy, radiopharmaceuticals, and medical isotope development.
Repare and CNL plan to leverage the strengths of both organizations which cut across radiobiology, preclinical evaluation, and the discovery of therapeutics that kill cancer cells by stopping the repair of DNA in cancer cells.
This work will potentially generate more insight into repair mechanisms associated with radiation-induced damage in DNA of cancer cells and hopefully lead to the development of therapeutics that can significantly enhance current radioligand therapies in cancer treatment for the benefit of Canadians and the world.
